RxDoctor Payments Data

Ashley Elliott, NP

Nurse Practitioner · Chester, VANPI 1619432762

Payments from drug & device makers

$2,738in general payments, 2019–2025

Across 86 payments — averaging $31.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$403
  • Novo Nordisk$337
  • Abbott$270
  • Amgen$221
  • Johnson & Johnson$205
  • Novartis$196
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,63896%
  • Education$893%
  • Entertainment$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,738 in reported general payments places this provider in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$34,616
Medicare patients
172
Services billed
569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$62,590
JardianceEmpagliflozin26$36,301
TrulicityDulaglutide26$26,751
JanuviaSitagliptin Phosphate16$25,811
EliquisApixaban15$18,125
LinzessLinaclotide14$11,721
Atorvastatin Calcium230$1,872
Albuterol Sulfate HfaAlbuterol Sulfate58$1,728
Aripiprazole18$1,553
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,496
Ezetimibe37$1,390
Amlodipine Besylate216$1,188
Levothyroxine Sodium127$1,183
Losartan Potassium118$896
Metoprolol Succinate55$884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$337$62,59052 claims
Boehringer IngelheimJardiance$403$36,30126 claims
Lilly USA, LLCTrulicity$59$26,75126 claims
MerckJanuvia$45$25,81116 claims
PfizerEliquis$67$18,12515 claims
AbbVieLinzess$45$11,72114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Chester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →